Danaher (DHR) Q3 2026: core growth 5.5% ex-respiratory and EPS guidance raised
FROM THE WIRE · GURUFOCUS.COM
Revenue: Q3 2026 sales of $6.6 billion.Core Revenue Growth: Up 3% overall; up 5.5% excluding respiratory revenue (100 bps acceleration from Q2).Respiratory Reve
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarterly results and a raised EPS guidance are relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 2026 sales were $6.6 billion.
- 02Core revenue grew 3% overall and 5.5% excluding respiratory revenue.
- 03EPS guidance was raised.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets